Ireland
--:--IST
Recruiting Phase 4

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions

NCT07617376 · tracked via the Priya Life Science Poland tracker
Phase
Phase 4
Started
2025-11-12
Last updated
2026-06-01

Condition(s) studied

Myocardial InfarctionDecompensated Chronic Heart FailureAcute Heart Failure (AHF)Pulmonary Embolism AcuteHypertension EmergencyArrhythmias

Investigational drug(s) / intervention(s)

Influenza vaccination →

Influenza vaccination: Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions

Study summary

Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.

In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Acute cardiac hospitalization, * Planned discharge home within the next 48 hours following completion of in-hospital treatment, * No prior influenza vaccination for the current influenza season. Exclusion Criteria: * History of a severe adverse reaction to influenza vaccination, * Allergy to any component of the vaccine to be administered, * Discharge to another hospital for continuation of treatment or discharge to a long-term care facility, * Antibiotic therapy to be continued after discharge.

Primary outcome measure(s)

  • infection, unplanned cardiovascular hospitalization or cardiovascular death — 6 months
    For the purposes of the study, infection was defined as an acute illness characterized by at least one of the following symptoms or events: * typical symptoms (malaise, fatigue, etc.), * self-measured body temperature of 38°C or higher, * the need for antipyretic / analgesic medication, * medical consultation (e.g. with general practitioner) due to infection, * unplanned hospitalization due to infection.

Trial sites (1)

FacilityCityRegionStatus
Jan Mikulicz Radecki University Hospital in Wroclaw Wroclaw Poland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07617376 on ClinicalTrials.gov ↗ ← All trials in Poland